1.北京市和平里医院眼科,北京100013
2.北京中医药大学东方医院眼科,北京100078
朱成义,男,45岁,硕士,副主任医师。研究方向:中西医结合诊疗眼底病及神经眼科疾病。
韦企平,E-mail: wei_dfyy@163.com
扫 描 看 全 文
朱成义,李冬,伊琼,等.黄斑消肿方联合雷珠单抗治疗气滞血瘀型视网膜分支静脉阻塞黄斑水肿的临床疗效[J].北京中医药,2022,41(7):786-790.
ZHU Cheng-yi,LI Dong,YI Qiong,et al.Clinical effect of Huangban Xiaozhong Decoction combined with ranibizumab on qi stagnation and blood stasis type of macular edema due to branch retinal vein occlusion[J]. Beijing Journal of Traditional Chinese Medicine,2022,41(07):786-790.
朱成义,李冬,伊琼,等.黄斑消肿方联合雷珠单抗治疗气滞血瘀型视网膜分支静脉阻塞黄斑水肿的临床疗效[J].北京中医药,2022,41(7):786-790. DOI: 10.16025/j.1674-1307.2022.07.021.
ZHU Cheng-yi,LI Dong,YI Qiong,et al.Clinical effect of Huangban Xiaozhong Decoction combined with ranibizumab on qi stagnation and blood stasis type of macular edema due to branch retinal vein occlusion[J]. Beijing Journal of Traditional Chinese Medicine,2022,41(07):786-790. DOI: 10.16025/j.1674-1307.2022.07.021.
目的,2,观察黄斑消肿方联合雷珠单抗治疗气滞血瘀型视网膜分支静脉阻塞黄斑水肿的临床效果。,方法,2,采用随机数字表的方法将62例(62只眼)气滞血瘀型视网膜分支静脉阻塞黄斑的患者分为对照组和观察组各31例(31只眼)。2组均给予玻璃体腔注射(IRI)雷珠单抗,注射次数为3次+必要时(PRN)。观察组在对照组治疗基础上,给予黄斑消肿方。2组研究周期为12个月。观察并对比2组疗效、中医证候总分、最佳矫正视力(BCVA)、黄斑中心区视网膜厚度(CST)、IRI注射次数及PRN间隔时间。,结果,2,治疗后,观察组总有效率高于对照组(,P,<,0.05)。治疗后1、6、12个月观察组中医证候总分、各症状积分、CST低于对照组(,P,<,0.05),BCVA高于对照组(,P,<,0.05)。观察组平均IRI注射次数是3(3,4)次,对照组平均IRI注射次数是5(4,6)次,2组平均IRI注射次数及PRN间隔时间比较差异有统计学意义(,P,<,0.05)。,结论,2,黄斑消肿方联合雷珠单抗治疗气滞血瘀型视网膜分支静脉阻塞黄斑水肿的临床效果优于单纯雷珠单抗治疗,可显著改善患者的中医证候,降低CST,提高BCVA,减少IRI注射次数,延长PRN间隔时间。
黄斑消肿方雷珠单抗视网膜分支静脉阻塞黄斑水肿气滞血瘀型
SONG P,XU Y,ZHA M,et al.Global epidemiology of retinal vein occlusion:a systematic review and meta-analysis of prevalence,incidence,and risk factors[J].J Glob Health,2019,9(1):010427.
JONAS JB,XU L,WANG YX.The Beijing eye study[J].Acta Ophthalmol, 2009,87(3):247-261.
ZHOU JQ,XU L,WANG S,et al.The 10-year incidence and risk factors of retinal vein occlusion: the Beijing eye study[J].Ophthalmology,2013,120(4):803-808.
HAYREH SS.Ocular vascular occlusive disorders: natural history of visual outcome[J].Prog Retin Eye Res,2014,41:1-25.
SCHMIDT-ERFURTH U,GARCIA-ARUMI J,GERENDAS BS,et al.Guidelines for the Management of Retinal Vein Occlusion by the European Society of Retina Specialists (EURETINA)[J].Ophthalmologica,2019,242(3):123-162.
陈露璐,陈有信.2019年《EURETINA视网膜静脉阻塞诊疗指南》解读[J].中华实验眼科杂志,2020,38(1):60-63.
王慧博,韦企平.韦企平治疗视网膜静脉阻塞临床经验[J].北京中医药,2014,33(5):348-350.
王晶莹,王建伟,张玮琼,等.基于“气血水”理论拟补阳汤加减方治疗糖尿病黄斑水肿探讨[J].北京中医药,2020,39(11):1150-1157.
肖文峥,谢立科,谢万坤,等.视网膜静脉阻塞的中医病机与治疗研究现状[J].北京中医药,2012,31(10):798-800.
HAYREH SS,ROJAS P,PODHAJSKY P,et al.Ocular neovascularization with retinal vascular occlusion-III.Incidence of ocular neovascularization with retinal vein occlusion[J].Ophthalmology,1983,90(5):488-506.
黎晓新.视网膜血管性疾病[M].北京:人民卫生出版社,2017:398-412.
国家中医药管理局医政司.22个专业95个病种中医诊疗方案[M].北京:中国中医药出版社,2011,15:344-346.
LI X,WANG N,LIANG X,et al.Safety and efficacy of dexamethasone intravitreal implant for treatment of macular edema secondary to retinal vein occlusion in Chinese patients:randomized,sham-controlled,multicenter study[J].Graefes Arch Clin Exp Ophthalmol,2018,256(1):59-69.
NOMA H,YASUDA K,SHIMURA M.Cytokines and the Pathogenesis of Macular Edema in Branch Retinal Vein Occlusion[J].J Ophthalmol,2019:5185128.
EBNETER A,KOKONA D,SCHNEIDER N,et al. Microglia Activation and Recruitment of Circulating Macrophages During Ischemic Experimental Branch Retinal Vein Occlusion[J].Invest Ophthalmol Vis Sci,2017,58(2):944-953.
O'MAHONEY PR,WONG DT,AY JG.Retinal vein occlusion and traditional risk factors for atherosclerosis[J].Arch Ophthalmol,2008,126(5):692-699.
NAKANO E,OTA T,JINGAMI Y,et al.Disorganization of the Retinal Inner Layers after Anti-VEGF Treatment for Macular Edema due to Branch Retinal Vein Occlusion[J].Ophthalmologica,2018,240(4):229-234.
郝晓凤,谢立科,胥静,等.祛积通络方联合抗VEGF治疗非缺血型视网膜分支静脉阻塞黄斑水肿的临床研究[J].中国中医眼科杂志,2020,30(4):244-249.
0
浏览量
0
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构